BiondVax Pharmaceuticals hits branding reset to become Scinai Immunotherapeutics amid a troubled year

Ben Adams - Sep 6, 2023

Israeli biotech company BiondVax Pharmaceuticals, which went public in 2015, has undergone significant changes, including a shift in focus and the appointment of a new CEO in 2021. As part of its transformation, the company is rebranding with a new name.

BiondVax is now Scinai Immunotherapeutics. While its roots were initially in the pursuit of a universal flu vaccine, the company has shifted its focus in R&D. Now, its endeavors include early-stage development of an inhaled COVID-19 therapy, a strategic autoimmune partnership with Max Planck Innovation and the establishment of a new CDMO business. That unit has also been renamed under the banner Scinai Bioservices and will be a strong core of the company.

The new corporate name is the biotech’s “latest step to better reflect its fresh start and new direction,” according to a press release. 

Article continues on fiercepharma.com